Kracie Pharma Ltd.

Takaoka, Japan

Kracie Pharma Ltd.

Takaoka, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
University of Toyama, Kracie Pharma Ltd., National Cancer Center and Tokyo University of Science | Date: 2015-04-10

The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.


Patent
Kracie Pharma Ltd., University of Toyama and National Cancer Center | Date: 2013-03-22

The present invention is intended to provide a burdock fruit extract comprising arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of approximately 1:1. A method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of arctigenin/arctiin =0.7 to 1.3 is provided, including the steps of: cutting a burdock fruit and converting arctiin which is inherent in the burdock fruit into arctigenin by enzymatic conversion by beta-glucosidase which is inherent in the burdock fruit, wherein the enzymatic conversion includes reaction at a temperature from 20 C. to 50 C. Also provided is the method further including a step of extracting an extract comprising arctigenin and arctiin by adding an organic solvent and heating to reflux.


Patent
Kracie Pharma Ltd., National Cancer Center and University of Toyama | Date: 2015-02-04

The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin = 0.7 to 1.3.


Patent
Kracie Pharma Ltd., National Cancer Center and University of Toyama | Date: 2014-09-24

The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.


Patent
Kracie Pharma Ltd., National Cancer Center and University of Toyama | Date: 2013-08-07

PROBLEM TO BE SOLVED The present invention is intended to provide a burdock fruit extract containing arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract containing arctigenin and arctiin at a weight ratio of approximately 1:1. SOLUTION A method for producing a burdock fruit extract containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin = 0.7 to 1.3 is provided, including the steps of: cutting a burdock fruit and converting arctiin which is inherent in the burdock fruit into arctigenin by enzymatic conversion by beta-glucosidase which is inherent in the burdock fruit, wherein the enzymatic conversion includes reaction at a temperature from 20C to 50C. Also provided is the method further including a step of extracting an extract containing arctigenin and arctiin by adding an organic solvent and heating to reflux.


Patent
Kracie Pharma Ltd., National Cancer Center and University of Toyama | Date: 2012-02-01

PROBLEM TO BE SOLVED A burdock fruit extract containing arctigenin at high content and its production method are provided, and both of which are used for treatment of pancreatic cancer. SOLUTION The burdock fruit extract containing arctigenin at high content by enzymatically converted arctiin into arctigenin with beta-glucosidase, which is an enzyme occurring endogenously in a burdock fruit, and adding ethanol, extracting, concentrating and then freeze-drying or spray drying.


Hamazaki-Fujita N.,Kracie Pharma Ltd.
Journal of cosmetic science | Year: 2012

Little is known about nonpathological facial skin problems at present. The aim of the present study was to investigate the relationships among facial skin conditions, mood, and the fatty acid composition of red blood cells (RBCs) in women. One hundred and thirty-two apparently healthy Japanese women aged between 20 and 60 years were recruited. Facial skin conditions were analyzed using a Robo Skin Analyzer, and the RBC fatty acid composition was also determined. Questionnaires concerning mood were administered. Forehead pigmentation was more mood-dependent (in 20s group) and less arachidonic acid (AA)-dependent (in all participants) than that in other areas of the face. Actually there was no correlation in pigmentation between the forehead and other areas of the face when adjusted for age, smoking, and drinking. Skin conditions were adversely correlated with a negative mood. α-Linolenic acid concentrations were negatively correlated with negative mood scores. Pigmentation characteristics in the forehead were independent from other areas of the face. Negative mood and AA were adversely correlated with skin conditions.


Patent
Kracie Pharma Ltd. | Date: 2011-09-23

A substance is disclosed that can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person and metabolic syndrome caused by the accumulation of a visceral fat. Specifically, a therapeutic and/or prophylactic agent for a sex hormone-dependent disease comprises at least one herbal extract selected from the group consisting of Kokeiten, prunella spike, sweet hydrangea leaf, milk thistle, a jasmine tea, Bokusoku, Tencha, Karensou, Youbaihi, French maritime pine, betel palm, asparagus, Rouro, Ryoukyou, rooibos tea, rhubarb, pu-erh tea, green tea, Ougon, St. Johns wort, licorice, Senrikou, wintergreen, Kashi, Yagotou, polygnum root, barrenwort, guarana, Ouhi, Argys wormwood, sticky rehmannia, Japanese cornel, Asiasarum root, cinnamon, peony root, pine needle and amla fruit.


PROBLEM TO BE SOLVED A burdock fruit extract containing arctigenin at high content and its production method are provided, and both of which are used for treatment of pancreatic cancer. SOLUTION The burdock fruit extract containing arctigenin at high content by enzymatically converted arctiin into arctigenin with beta-glucosidase, which is an enzyme occurring endogenously in a burdock fruit, and adding ethanol, extracting, concentrating and then freeze-drying or spray drying.


Patent
Kracie Pharma Ltd. | Date: 2011-09-23

A substance is disclosed that can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person and metabolic syndrome caused by the accumulation of a visceral fat. Specifically, a therapeutic and/or prophylactic agent for a sex hormone-dependent disease comprises at least one herbal extract selected from the group consisting of Kokeiten, prunella spike, sweet hydrangea leaf, milk thistle, a jasmine tea, Bokusoku, Tencha, Karensou, Youbaihi, French maritime pine, betel palm, asparagus, Rouro, Ryoukyou, rooibos tea, rhubarb, pu-erh tea, green tea, Ougon, St. Johns wort, licorice, Senrikou, wintergreen, Kashi, Yagotou, polygnum root, barrenwort, guarana, Ouhi, Argys wormwood, sticky rehmannia, Japanese cornel, Asiasarum root, cinnamon, peony root, pine needle and amla fruit.

Loading Kracie Pharma Ltd. collaborators
Loading Kracie Pharma Ltd. collaborators